Another step in understanding the genomic classification of prostate cancer

Prostate cancer is a leading cause of cancer death in the United States. This lethal disease is very heterogeneous both genomically and clinically. Even patients with advanced disease may have very different clinical course as well as varied responses to our most novel therapies. As in most cancers, improved knowledge of the genomic landscape may lead to improved prognostication and an enhanced selection of therapies specific to particular subtypes which would improve the patient experience. The referenced article by Boysen et al. (1) has contributed to an improved understanding of the clinical genomics of prostate cancer.